| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Monoamine oxidase B (MAO-B), a mitochondrial enzyme responsible for the oxidative deamination of dopamine and other monoamine neurotransmitters. Rasagiline (unlabeled) is a highly potent, selective, and irreversible inhibitor of MAO-B with an IC50 of 4.43 nM for rat brain MAO-B. It exhibits approximately 100-fold selectivity for MAO-B over MAO-A (IC50 of 412 nM for rat brain MAO-A). The 13C3-labeled version has identical target affinity and selectivity.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as tracers that influence measurement during the drug development process. It's possible that the pharmacokinetics and functional range of medications contribute to the concern over mutagenesis [1].
In vitro, rasagiline (unlabeled) potently and irreversibly inhibits MAO-B activity in homogenates of brain tissue. It binds covalently to the flavin adenine dinucleotide (FAD) cofactor of MAO-B, leading to sustained enzyme inactivation. The inhibition is time-dependent and irreversible upon washout. Rasagiline has minimal effects on MAO-A at therapeutic concentrations, preserving serotonin metabolism. The 13C3-labeled version has identical in vitro activity but is used as an analytical internal standard for quantitation in research samples. |
| ln Vivo |
In vivo, rasagiline (unlabeled) is used clinically as a monotherapy for early Parkinson's disease and as an adjunct to levodopa in moderate-to-advanced stages. By inhibiting MAO-B, rasagiline increases striatal dopamine levels, reducing motor symptoms such as rigidity, bradykinesia, and tremor. It also exhibits neuroprotective effects in preclinical models, which may be due to reduced oxidative stress from decreased dopamine metabolism. The 13C3-labeled version is used as an internal standard for pharmacokinetic studies.
|
| Enzyme Assay |
A standard in vitro MAO-B inhibition assay is performed using purified MAO-B enzyme (e.g., recombinant human MAO-B) or tissue homogenates (e.g., rat brain mitochondria). The substrate is typically kynuramine (which is converted to 4-hydroxyquinoline upon deamination) or a radiolabeled substrate such as 14C-phenylethylamine (PEA). The assay is performed by pre-incubating the test compound (rasagiline or its labeled analog) with the enzyme for a defined period (e.g., 30 minutes) at 37degC, then adding the substrate and measuring the product formation by fluorescence (excitation 315 nm, emission 380 nm) or scintillation counting. The half-maximal inhibitory concentration (IC50) is determined from dose-response curves.
|
| Cell Assay |
In vitro cellular assays for MAO-B inhibition can be performed using SH-SY5Y human neuroblastoma cells (which express MAO-B) or primary astrocytes. Cells are treated with varying concentrations of rasagiline (or the 13C3-labeled version) for 24-48 hours. MAO-B activity is measured by lysing the cells and incubating the lysate with a MAO-B-specific substrate (e.g., benzylamine or PEA) and a detection reagent (e.g., Amplex Red horseradish peroxidase-coupled assay). Fluorescence is measured to calculate IC50 values. Alternatively, cellular dopamine levels can be measured by HPLC-ECD as an indirect readout of MAO-B inhibition.
|
| Animal Protocol |
In vivo animal studies for rasagiline are typically conducted in rodent models of Parkinson's disease, such as the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model. Mice are administered MPTP to induce dopaminergic neuron degeneration in the substantia nigra. Rasagiline (or the labeled analog) is then administered at various doses (e.g., 0.5-5 mg/kg) via oral gavage or intraperitoneal injection, typically once daily for 5-10 days. Endpoints include assessment of motor function (rotarod, open field), striatal dopamine levels (HPLC-ECD), tyrosine hydroxylase (TH) immunohistochemistry, and measurement of MAO-B activity in brain homogenates. The 13C3-labeled compound can be used as an internal standard for quantifying rasagiline levels in brain and plasma.
|
| ADME/Pharmacokinetics |
Rasagiline is rapidly absorbed after oral administration, with a Tmax of approximately 1 hour. It has an oral bioavailability of about 35% in humans due to extensive first-pass metabolism. The elimination half-life is approximately 3 hours. Rasagiline is extensively metabolized by CYP1A2, primarily to 1-(R)-aminoindan (major metabolite, which is inactive) and hydroxyrasagiline (minor). The 13C3-labeled version has identical ADME properties and is used as an internal standard in pharmacokinetic studies.
|
| Toxicity/Toxicokinetics |
Rasagiline mesylate has a well-established safety profile based on extensive clinical use. The most common adverse events include headache, dyspepsia, arthralgia, flu-like symptoms, and depression. As an MAO-B inhibitor at therapeutic doses, it has low risk of hypertensive crisis (cheese effect) because MAO-A (which metabolizes tyramine) is not significantly inhibited. However, caution is required when co-administered with serotonergic drugs (e.g., SSRIs, SNRIs) due to risk of serotonin syndrome. The 13C3-labeled version is an analytical standard for use in mass spectrometry and is not for human administration.
|
| References |
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
|
| Additional Infomation |
Rasagiline-13C3 mesylate is a stable isotope-labeled internal standard for the quantification of rasagiline by GC-MS or LC-MS in bioanalytical studies. Rasagiline mesylate (brand names Azilect, Anpo, Torreal) is an FDA-approved and EMA-approved medication for the treatment of Parkinson's disease, both as monotherapy and as adjunctive therapy with levodopa. The unlabeled drug is a second-generation MAO-B inhibitor with greater selectivity than selegiline. The 13C3-labeled version is strictly a research-grade analytical standard for pharmacokinetic and bioanalytical method development.
|
| Molecular Formula |
C1013C3H17NO3S
|
|---|---|
| Molecular Weight |
270.32
|
| Exact Mass |
270.102
|
| CAS # |
1391052-18-8
|
| Related CAS # |
Rasagiline mesylate;161735-79-1
|
| PubChem CID |
71751983
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
18
|
| Complexity |
305
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1=CC=C2[C@H](N[13CH2][13C]#[13CH])CCC2=C1.S(C)(=O)(O)=O
|
| InChi Key |
JDBJJCWRXSVHOQ-UAWGACSXSA-N
|
| InChi Code |
InChI=1S/C12H13N.CH4O3S/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12;1-5(2,3)4/h1,3-6,12-13H,7-9H2;1H3,(H,2,3,4)/t12-;/m1./s1/i1+1,2+1,9+1;
|
| Chemical Name |
methanesulfonic acid;(1R)-N-(1,2,3-13C3)prop-2-ynyl-2,3-dihydro-1H-inden-1-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6993 mL | 18.4966 mL | 36.9932 mL | |
| 5 mM | 0.7399 mL | 3.6993 mL | 7.3986 mL | |
| 10 mM | 0.3699 mL | 1.8497 mL | 3.6993 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
